Research company BioArctic's partner Eisai will present new long-term results for the Alzheimer's drug lecanemab at the AD/PD conference in Copenhagen, March 17–21, according to a press release.

The presentations include data from clinical use of the drug as well as four-year data from the open-label extension study of Clarity AD.

BioArctic will also give an oral presentation on lecanemab and display a poster related to exidavnemab in Parkinson's disease.